Best GLP-1 for Weight Loss

Ranked Overview

The following rankings are based on average weight loss observed in pivotal clinical trials. It is important to note that individual results vary significantly, and cross-trial comparisons have inherent limitations (differences in patient populations, trial design, and duration). These rankings are intended as a general reference, not a recommendation for any individual.

#1: Zepbound (Tirzepatide)

Zepbound (tirzepatide, manufactured by Eli Lilly) is a dual GIP/GLP-1 receptor agonist approved by the FDA for chronic weight management.

Clinical trial data (SURMOUNT-1): In the SURMOUNT-1 trial, participants receiving the highest dose of tirzepatide (15 mg) achieved an average weight loss of 22.5% of body weight over 72 weeks. Lower doses (5 mg and 10 mg) produced average reductions of 16.0% and 21.4%, respectively. The trial enrolled adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity, but without diabetes.

These results represent some of the largest weight reductions achieved with any anti-obesity medication in clinical trials.

#2: Wegovy (Semaglutide)

Wegovy (semaglutide 2.4 mg, manufactured by Novo Nordisk) is a GLP-1 receptor agonist approved for chronic weight management.

Clinical trial data (STEP 1): In the STEP 1 trial, participants receiving semaglutide 2.4 mg achieved an average weight loss of 16.9% of body weight over 68 weeks compared to 2.4% with placebo. STEP 1 enrolled adults without diabetes who had a BMI of 30 or greater, or 27 or greater with at least one weight-related condition.

Wegovy also demonstrated cardiovascular benefit in the SELECT trial, which showed a 20% reduction in major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease.

#3: Saxenda (Liraglutide)

Saxenda (liraglutide 3.0 mg, manufactured by Novo Nordisk) is a GLP-1 receptor agonist approved for weight management. It requires daily injections, compared to the once-weekly dosing of Wegovy and Zepbound.

Clinical trial data (SCALE): In the SCALE trial, participants receiving liraglutide 3.0 mg achieved an average weight loss of approximately 8% of body weight over 56 weeks compared to 2.6% with placebo.

While Saxenda produces more modest weight loss than newer agents, it has a longer track record and may be an option when other medications are unavailable or not tolerated.

Head-to-Head Data: SURMOUNT-5

The SURMOUNT-5 trial provided the first direct comparison of tirzepatide and semaglutide for weight loss. In this head-to-head study, participants receiving tirzepatide achieved greater average weight loss than those receiving semaglutide. These results were consistent across dose levels and supported the ranking of tirzepatide above semaglutide for weight reduction, though both medications produced clinically meaningful results.

Head-to-head trials provide more reliable comparisons than cross-trial analyses because they evaluate medications under the same conditions and in the same patient population.

Important Note: Ozempic and Mounjaro

Ozempic (semaglutide 1.0 mg/2.0 mg) and Mounjaro (tirzepatide) are FDA-approved for type 2 diabetes, not for weight management. While they contain the same active ingredients as Wegovy and Zepbound, respectively, they are approved at different doses and for different indications. Off-label prescribing of these medications for weight loss is common but may affect insurance coverage and may not reflect the dosing studied in weight management trials.

Cost Considerations

GLP-1 medications for weight management carry significant costs:

• List prices for Zepbound and Wegovy typically exceed $1,000 per month without insurance.
• Insurance coverage for weight management medications varies widely. Many commercial plans, Medicare Part D, and Medicaid programs either do not cover anti-obesity medications or impose strict prior authorization requirements.
• Manufacturer savings programs may reduce out-of-pocket costs for commercially insured patients, but eligibility and discounts change frequently.

Cost should be discussed openly with a healthcare provider and pharmacist, as it may influence which medication is most practical for a given patient.

Insurance Reality

Access to GLP-1 medications for weight loss remains a significant barrier for many patients. Common challenges include:

• Prior authorization requirements with extensive documentation
• Step therapy mandates requiring trials of other medications first
• Annual or lifetime coverage limits
• Complete exclusion of weight management medications from some formularies

Patients are encouraged to work with their prescriber's office and insurance plan to understand coverage options before starting treatment.

Important Caveats

• Cross-trial limitations: Rankings based on different clinical trials should be interpreted cautiously. Differences in patient demographics, baseline weight, trial duration, diet and exercise protocols, and dropout rates can all influence reported outcomes.
• Individual variation: Clinical trial averages do not predict any individual's response. Some patients may achieve substantially more or less weight loss than the trial average.
• Side effects: All GLP-1 medications carry risks of side effects, most commonly gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation. These should be weighed against potential benefits.
• Long-term use: Weight management with GLP-1 medications generally requires ongoing treatment. Studies have shown significant weight regain after discontinuation.
• Not a substitute for lifestyle changes: These medications are approved as an adjunct to a reduced-calorie diet and increased physical activity, not as standalone treatments.

This content is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider to discuss which treatment may be appropriate for your individual circumstances.